Neumora Therapeutics Inc (NMRA)
1.0650 -0.0350 (-3.18%) 12:30 ET [NASDAQ]
1.0600 x 100 1.0700 x 345
Realtime by (Cboe BZX)
1.0600 x 100 1.0700 x 345
Realtime 1.0900 -0.0100 (-0.91%) 09:19 ET
for Fri, Mar 28th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
Cash Flows From Operating Activities | |||||
Net Income | -243,787 | -184,968 | -112,421 | -53,721 | -235,925 |
Depreciation Amortization | -5,088 | -4,164 | -2,994 | -989 | -3,073 |
Accounts payable and accrued liabilities | 2,873 | 5,770 | 745 | 1,155 | -581 |
Other Working Capital | 22,636 | 23,992 | -5,442 | 3,591 | -8,899 |
Other Operating Activity | 40,430 | 26,774 | 20,999 | 7,009 | 85,200 |
Operating Cash Flow | $-182,936 | $-132,596 | $-99,113 | $-42,955 | $-163,278 |
Cash Flows From Investing Activities | |||||
PPE Investments | N/A | N/A | N/A | N/A | -117 |
Purchase Of Investment | -312,223 | -205,324 | -205,340 | -185,804 | -109,072 |
Sale Of Investment | 242,441 | 234,341 | 77,369 | 36,578 | 178,166 |
Other Investing Activity | -775 | -775 | -775 | -775 | -4,590 |
Investing Cash Flow | $-70,557 | $28,242 | $-128,746 | $-150,001 | $64,387 |
Cash Flows From Financing Activities | |||||
Common Stock Issued | 21,176 | 6,255 | 4,499 | 1,845 | 236,231 |
Common Stock Repurchased | N/A | N/A | N/A | N/A | -491 |
Other Financing Activity | 427 | -225 | 0 | 0 | -3,804 |
Financing Cash Flow | $21,603 | $6,030 | $4,499 | $1,845 | $231,936 |
Beginning Cash Position | 375,251 | 375,251 | 375,251 | 375,251 | 242,206 |
End Cash Position | 143,361 | 276,927 | 151,891 | 184,140 | 375,251 |
Net Cash Flow | $-231,890 | $-98,324 | $-223,360 | $-191,111 | $133,045 |
Free Cash Flow | |||||
Operating Cash Flow | -182,936 | -132,596 | -99,113 | -42,955 | -163,278 |
Capital Expenditure | N/A | N/A | N/A | N/A | -117 |
Free Cash Flow | -182,936 | -132,596 | -99,113 | -42,955 | -163,395 |